奈达铂、替加氟联合紫杉醇治疗晚期食管癌的近期疗效观察

目的：观察奈达铂（NDP）、替加氟（rt-207）联合紫杉醇（PTx）治疗晚期食管癌的近期疗效及安全性。方法：选择2008年3月至2010年6月在我院治疗的65例晚期食管癌患者，应用NDP20mg／m2，静脉滴注，第1～3天；Ft--207500mg／m2，静脉滴注射，第1～5天；PTx135～175mg／m2，静脉滴注，第1天；21天为1个周期，至少2个周期后评价疗效和毒副反应的发生情况。结果：除1例因奈达铂过敏反应停药外，共64例患者完成化疗并可评价疗效。该方案总体有效率（RR）为56．3％，其中完全缓解（CR）3例（占4．7％），部分缓解（PR）33例（占51．6％），病情稳定（SD）17例（占26．6％），另有11例（占17．2％）出现不同程度的疾病进展（PD）。仅1例出现可控制的Ⅳ度骨髓抑制。结论：NDP、Ft-207联合PTx对晚期食管癌近期疗效肯定，安全性好，值得临床推广应用。

Clinical Observation on Combined Chemotherapy with Nedaplatin, Tegafur and Paclitaxel in Advanced Esophageal Carcinoma

Objective： To investigate the efficacy and safety of the chemotherapy regimen with nedaplatin, tegafur and paclitaxel in advanced tesophageal carcinoma. Methods： Sixty-five patients with pathologically confirmed advanced esophageal carcinoma admitted in our hospital from March 2008 to June 2010 were chosen, and were treated with three-week intravenous chemotherapy regimen with NDP 20 mg/m2, dl-d3, Ft-207 500 mg/m2, dl-d5, and PTx 135-175mg/m2, dl. A treatment cycle was 28 days. The Efficacy and toxicity were evaluated after at least 2 treatment cycles. Results： In 65 cases, only one patient had to quit for allergic reaction to NDP in the first cycle, the other sixty-four patients were eligible for clinical response evaluation, in which the overall response rate was 57.8%, the com- plete remission rate was 4.7% （n=3）, the partial remission rate was 51.6% （n=33） and the stable rate was 26.6% （n=17）, in addition to 17.2% disease progress （n=l 1）. Only one patient encountered a controllable bone marrow depression of grade IV. Conclusion： The com- bined chemotherapy with PTX, NDP and Ft-207 is effective and safe in advanced esophageal cancer, and is worth of further generaliza- tion.